Pursuing the Complexity of Alzheimer’s Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists
Authors:
- Jan KonecnyJKJan Konecny
- Anna MisiachnaAMAnna Misiachna
- Martina HrabinovaMHMartina Hrabinova
- Lenka PulkrabkovaLPLenka Pulkrabkova
- Marketa BenkovaMBMarketa Benkova
- Lukas PrchalLPLukas Prchal
- Tomas KuceraTKTomas Kucera
- Tereza KobrlovaTKTereza Kobrlova
- Vladimir FingerVFVladimir Finger
- Marharyta KolchevaMKMarharyta Kolcheva
- Stepan KortusSKStepan Kortus
- Daniel JunDJDaniel Jun
Open Access
- 22 December 2020
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 11 (1) , 3
Abstract
Alzheimer’s disease (AD) is a complex disorder with unknown etiology. Currently, only symptomatic therapy of AD is available, comprising cholinesterase inhibitors and N-methyl-d-aspartate (NMDA) receptor antagonists. Drugs targeting only one pathological condition have generated only limited efficacy. Thus, combining two or more therapeutic interventions into one molecule is believed to provide higher benefit for the treatment of AD. In the presented study, we designed, synthesized, and biologically evaluated 15 novel fluoren-9-amine derivatives. The in silico prediction suggested both the oral availability and permeation through the blood–brain barrier (BBB). An initial assessment of the biological profile included determination of the cholinesterase inhibition and NMDA receptor antagonism at the GluN1/GluN2A and GluN1/GluN2B subunits, along with a low cytotoxicity profile in the CHO-K1 cell line. Interestingly, compounds revealed a selective butyrylcholinesterase (BChE) inhibition pattern with antagonistic activity on the NMDARs. Their interaction with butyrylcholinesterase was elucidated by studying enzyme kinetics for compound 3c in tandem with the in silico docking simulation. The docking study showed the interaction of the tricyclic core of new derivatives with Trp82 within the anionic site of the enzyme in a similar way as the template drug tacrine. From the kinetic analysis, it is apparent that 3c is a competitive inhibitor of BChE.Keywords
Funding Information
- Agentura Pro Zdravotnický Výzkum České Republiky (NU20-08-00296)
- Faculty of Military Health Sciences, University of Defence (FVZ201803, Long-term development plan)
- MH CZ - DRO (00179906)
- European Regional Development Fund: Project "PharmaBrain" (CZ.02.1.01/0.0/0.0/16_025/0007444)
- "e-Infrastruktura CZ" (INFRA LM2018140)
- Univerzita Karlova v Praze (SVV 260 547)
This publication has 85 references indexed in Scilit:
- Oximes: Inhibitors of Human Recombinant Acetylcholinesterase. A Structure-Activity Relationship (SAR) StudyInternational Journal of Molecular Sciences, 2013
- The hCMEC/D3 cell line as a model of the human blood brain barrierFluids and Barriers of the CNS, 2013
- Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important LigandsJournal of Medicinal Chemistry, 2012
- Single amino acid residue in the M4 domain of GluN1 subunit regulates the surface delivery of NMDA receptorsJournal of Neurochemistry, 2012
- Characteristics of known drug space. Natural products, their derivatives and synthetic drugsEuropean Journal of Medicinal Chemistry, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer’s diseaseInternational Journal of Experimental Pathology, 2008
- Conformational changes and cleavage of tau in Pick bodies parallel the early processing of tau found in Alzheimer pathologyNeuropathology and Applied Neurobiology, 2007
- Global prevalence of dementia: a Delphi consensus studyThe Lancet, 2005
- Clinical Pharmacokinetics of TacrineClinical Pharmacokinetics, 1995